Cigniti Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 8:13 am

Competitors of Cigniti Technologies Ltd

All Competitor Stocks of Cigniti Technologies Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:40 pm

Below is a detailed analysis of the quarterly data for Cigniti Technologies Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 534.00 Cr.. The value appears strong and on an upward trend. It has increased from 530.00 Cr. (Mar 2025) to 534.00 Cr., marking an increase of 4.00 Cr..
• For Expenses, as of Jun 2025, the value is 445.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 441.00 Cr. (Mar 2025) to 445.00 Cr., marking an increase of 4.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 1.00 Cr..
• For OPM %, as of Jun 2025, the value is 17.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00%.
• For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 9.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 8.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 26.00%, marking an increase of 1.00%.
• For Net Profit, as of Jun 2025, the value is 66.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 7.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 24.05. The value appears to be declining and may need further review. It has decreased from 26.72 (Mar 2025) to 24.05, marking a decrease of 2.67.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:33 am

Growth

Last Updated: September 5, 2025, 1:55 am

Balance Sheet

Last Updated: November 9, 2025, 1:50 pm

Below is a detailed analysis of the balance sheet data for Cigniti Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 28.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,101.00 Cr.. The value appears strong and on an upward trend. It has increased from 936.00 Cr. (Mar 2025) to 1,101.00 Cr., marking an increase of 165.00 Cr..
• For Borrowings, as of Sep 2025, the value is 20.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 28.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 8.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 330.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 248.00 Cr. (Mar 2025) to 330.00 Cr., marking an increase of 82.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 1,479.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,239.00 Cr. (Mar 2025) to 1,479.00 Cr., marking an increase of 240.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 121.00 Cr. (Mar 2025) to 107.00 Cr., marking a decrease of 14.00 Cr..
• For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Investments, as of Sep 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 146.00 Cr. (Mar 2025) to 41.00 Cr., marking a decrease of 105.00 Cr..
• For Other Assets, as of Sep 2025, the value is 1,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 973.00 Cr. (Mar 2025) to 1,331.00 Cr., marking an increase of 358.00 Cr..
• For Total Assets, as of Sep 2025, the value is 1,479.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,239.00 Cr. (Mar 2025) to 1,479.00 Cr., marking an increase of 240.00 Cr..

Notably, the Reserves (1,101.00 Cr.) exceed the Borrowings (20.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Cigniti Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 72.77. This value is within the healthy range. It has increased from 60.68 (Mar 24) to 72.77, marking an increase of 12.09.
• For Diluted EPS (Rs.), as of Mar 25, the value is 72.77. This value is within the healthy range. It has increased from 60.41 (Mar 24) to 72.77, marking an increase of 12.36.
• For Cash EPS (Rs.), as of Mar 25, the value is 85.54. This value is within the healthy range. It has increased from 71.77 (Mar 24) to 85.54, marking an increase of 13.77.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 351.59. It has increased from 270.36 (Mar 24) to 351.59, marking an increase of 81.23.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 351.59. It has increased from 270.36 (Mar 24) to 351.59, marking an increase of 81.23.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 744.02. It has increased from 673.00 (Mar 24) to 744.02, marking an increase of 71.02.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 123.83. This value is within the healthy range. It has increased from 93.34 (Mar 24) to 123.83, marking an increase of 30.49.
• For PBIT / Share (Rs.), as of Mar 25, the value is 111.35. This value is within the healthy range. It has increased from 82.23 (Mar 24) to 111.35, marking an increase of 29.12.
• For PBT / Share (Rs.), as of Mar 25, the value is 99.29. This value is within the healthy range. It has increased from 80.72 (Mar 24) to 99.29, marking an increase of 18.57.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 73.06. This value is within the healthy range. It has increased from 60.66 (Mar 24) to 73.06, marking an increase of 12.40.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 73.06. This value is within the healthy range. It has increased from 60.66 (Mar 24) to 73.06, marking an increase of 12.40.
• For PBDIT Margin (%), as of Mar 25, the value is 16.64. This value is within the healthy range. It has increased from 13.86 (Mar 24) to 16.64, marking an increase of 2.78.
• For PBIT Margin (%), as of Mar 25, the value is 14.96. This value is within the healthy range. It has increased from 12.21 (Mar 24) to 14.96, marking an increase of 2.75.
• For PBT Margin (%), as of Mar 25, the value is 13.34. This value is within the healthy range. It has increased from 11.99 (Mar 24) to 13.34, marking an increase of 1.35.
• For Net Profit Margin (%), as of Mar 25, the value is 9.82. This value is within the healthy range. It has increased from 9.01 (Mar 24) to 9.82, marking an increase of 0.81.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.82. This value is within the healthy range. It has increased from 9.01 (Mar 24) to 9.82, marking an increase of 0.81.
• For Return on Networth / Equity (%), as of Mar 25, the value is 20.78. This value is within the healthy range. It has decreased from 22.43 (Mar 24) to 20.78, marking a decrease of 1.65.
• For Return on Capital Employeed (%), as of Mar 25, the value is 30.81. This value is within the healthy range. It has increased from 29.12 (Mar 24) to 30.81, marking an increase of 1.69.
• For Return On Assets (%), as of Mar 25, the value is 16.15. This value is within the healthy range. It has decreased from 16.46 (Mar 24) to 16.15, marking a decrease of 0.31.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.82. It has decreased from 1.98 (Mar 24) to 1.82, marking a decrease of 0.16.
• For Current Ratio (X), as of Mar 25, the value is 4.39. This value exceeds the healthy maximum of 3. It has increased from 3.67 (Mar 24) to 4.39, marking an increase of 0.72.
• For Quick Ratio (X), as of Mar 25, the value is 4.39. This value exceeds the healthy maximum of 2. It has increased from 3.67 (Mar 24) to 4.39, marking an increase of 0.72.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.00 (Mar 24) to 0.00, marking a decrease of 14.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.83 (Mar 24) to 0.00, marking a decrease of 11.83.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 86.00 (Mar 24) to 0.00, marking a decrease of 86.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.17 (Mar 24) to 0.00, marking a decrease of 88.17.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 113.77. This value is within the healthy range. It has increased from 61.82 (Mar 24) to 113.77, marking an increase of 51.95.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 78.20. This value is within the healthy range. It has increased from 41.17 (Mar 24) to 78.20, marking an increase of 37.03.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,744.10. It has increased from 3,332.03 (Mar 24) to 3,744.10, marking an increase of 412.07.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has increased from 1.81 (Mar 24) to 1.84, marking an increase of 0.03.
• For EV / EBITDA (X), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 11.04, marking a decrease of 2.04.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 1.96, marking an increase of 0.08.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 85.99 (Mar 24) to 0.00, marking a decrease of 85.99.
• For Price / BV (X), as of Mar 25, the value is 4.15. This value exceeds the healthy maximum of 3. It has decreased from 4.68 (Mar 24) to 4.15, marking a decrease of 0.53.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.96. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 1.96, marking an increase of 0.08.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness